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Cardiotoxicity with vascular endothelial growth factor
inhibitor therapy
Rhian M. Touyz 1 and Joerg Herrmann2
Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signaling pathway (VSP) have been important
additions in the therapy of various cancers, especially renal cell carcinoma and colorectal cancer. Bevazicumab, the ﬁrst VSP to
receive FDA approval in 2004 targeting all circulating isoforms of VEGF-A, has become one of the best-selling drugs of all times. The
second wave of tyrosine kinase inhibitors (TKIs), which target the intracellular site of VEGF receptor kinases, began with the
approval of sorafenib in 2005 and sunitinib in 2006. Heart failure was subsequently noted, in 2–4% of patients on bevacizumab and
in 3–8% of patients on VSP-TKIs. The very fact that the single-targeted monoclonal antibody bevacizumab can induce cardiotoxicity
supports a pathomechanistic role for the VSP and the postulate of the “vascular” nature of VSP inhibitor cardiotoxicity. In this review
we will outline this scenario in greater detail, reﬂecting on hypertension and coronary artery disease as risk factors for VSP inhibitor
cardiotoxicity, but also similarities with peripartum and diabetic cardiomyopathy. This leads to the concept that any preexisting or
coexisting condition that reduces the vascular reserve or utilizes the vascular reserve for compensatory purposes may pose a risk
factor for cardiotoxicity with VSP inhibitors. These conditions need to be carefully considered in cancer patients who are to undergo
VSP inhibitor therapy. Such vigilance is not to exclude patients from such prognostically extremely important therapy but to
understand the continuum and to recognize and react to any cardiotoxicity dynamics early on for superior overall outcomes.
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INTRODUCTION
Angiogenesis inhibitors have turned into clinical reality the
pioneering vision of Dr. Judah Folkman’s that new blood vessel
formation is critical for the growth of tumors and that anti-
angiogenic therapy is key to tumor regression.1 Bevacizumab, a
humanized monoclonal antibody directed against all isoforms of
vascular endothelial growth factor (VEGF)-A, was the ﬁrst targeted
angiogenesis inhibitor to be developed. Since its approval in the
US in 2004, it has emerged as one of the top ten best-selling drugs
of all times, generating over US$60 billion in sales through 2016
(source: Forbes (1996 through 2012) and company-reported data
from 2013–2016). World-wide, angiogenesis inhibitors approved
for the treatment of malignancies have generated sales in excess
of US$ 10 billion in 2014 alone (source: EvaluatePharma).
In patients with colorectal cancer and non-squamous cell lung
cancer, the addition of the angiogenesis inhibitor bevacizumab
doubled the progression-free survival. Similarly, in patients with
metastatic renal cell carcinoma, sunitinib more than doubled
overall survival over next line comparator therapy.2 The interested
reader is referred to a recent review summarizing key Phase III
clinical trial data for VEGF-inhibitors in advanced cancer.3 As
testiﬁed, this class of drugs has emerged as a tremendous success
story in health care.
On the other hand, adverse effects have been noted, including
cardiovascular toxicities. These include both vascular, as well as
cardiac side effects, which should not be a surprise based on the
pivotal role of VEGF for the development and functional integrity
of the vasculature and the importance of the vasculature for heart
function. In this article we review the incidence, risk factors, and
mechanisms of cardiac toxicity of angiogenesis inhibitors, namely
those targeting the VEGF signaling pathway (VSP), and conclude
with an outline of management options for clinical practice. The
spectrum covered herein spans from hypertension to athero-
sclerosis, arterial thrombotic events, and heart failure. In particular,
we aim to convey how the ﬁrst three vascular toxicity proﬁles can
ultimately culminate in cardiac disease. The content is based on a
PubMed literature search covering the years 1960–2017 and using
the search terms “angiogenesis inhibitor, arterial thrombotic
events, atherosclerosis, cancer, cardiomyopathy, cardiotoxicity,
chemotherapy, coronary artery disease (CAD), diabetes, heart
failure, hypertension, hypothyroidism, obstructive sleep apnea
(OSA), preeclampsia, vascular, VEGF, and VEGF inhibitor.”
CARDIOVASCULAR EVENTS WITH VSP INHIBITORS
A number of cancer drugs, by virtue of their inhibitory effects on
vascular growth signaling, can affect the survival and proliferation
of endothelial and vascular smooth muscle cells and thus can
exert an anti-angiogenic effect.4 However, no other growth factor
signaling pathway has been as inherently entwined with
angiogenesis as the VSP. Accordingly, VSP inhibitors are the
epitome of this diverse class of drugs and will be the focus of this
review (Table 1).
Conceptually, the VSP can be inhibited on the level of the ligand
or the extracellular or intracellular domain of the VEGF receptor.5
Pharmacologically two approaches are used to do so.5 The ﬁrst
entails monoclonal antibodies against the extracellular VSP
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components: VEGF isoforms (VEGF-A: bevacizumab and VEGF-A/
VEGF-B/placental growth factor: aﬂibercept) and the VEGF
receptor 2 (ramucirumab). The second approach comprises
inhibitors of the tyrosine kinase activity of the intracellular domain
of the VEGF receptor(s), which, however, is not as speciﬁc leading
to diverse inhibitory proﬁles of (mainly receptor) tyrosine kinases.
Collectively, VSP inhibitors almost universally lead to an increase
in blood pressure, the extent of which may vary, and depending
on the blood pressure cut-offs used, various studies have reported
varying levels of incidences. As outlined in a recent and most
comprehensive meta-analysis of 77 VSP inhibitor studies, on
average, severe hypertension is noted in 7.4% of patients, arterial
thromboembolism in 1.8%, cardiac ischemic in 1.7%, and cardiac
dysfunction in 2.3%.6 Overall, VSP inhibitors increase the odds of
hypertension/severe hypertension, cardiac ischemia, arterial
thromboembolism and cardiac dysfunction 5.3/5.6, 2.8, 1.5, and
1.4 times, respectively. A more tangible expression of risk,
however, might be the number needed to harm, which is 6 and
17 for hypertension and severe hypertension, respectively. In
comparison, 141 patients would need to be treated with VEGF
inhibitor therapy for one arterial thromboembolic event to occur,
139 patients for one case of cardiac dysfunction to be noted, and
410 patients for one clinical heart failure (CHF) presentation to
evolve. Cardiac ischemia may develop in 1 in 85 patients on VEGF
inhibitor therapy, but the robustness of data is more limited as
only eight studies were included for analysis of this endpoint
(versus 71 studies for severe hypertension). Importantly, the risk of
a fatal cardiovascular event with VEGF inhibitor therapy is very
small, only 0.25%, or alternatively expressed, 1259 patients would
need to be treated for one fatal event to occur. As such, it is
important to emphasize that the risk-beneﬁt balance of VSP
inhibitors is heavily weighted toward using these agents rather
than withholding them, especially as these agents are predomi-
nantly used in patients with metastatic malignancy, whose
treatment options are limited.
CAD AS A RISK FACTOR FOR CARDIOTOXICITY WITH VSP
INHIBITORS
It stands to reason how much the cardiovascular events with VSP
inhibitors are mechanistically related. Though only in a relatively
small number of patients (n= 175), a very insightful study by Di
Lorenzo et al.7 identiﬁed CAD and hypertension as the most
important predictors for the development of heart failure with the
VSP-TKI sunitinib. Importantly, all seven patients with a CAD
history were among those 12 patients who developed CHF while
on sunitinib. Accordingly, the positive predictive value of CAD for
CHF with sunitinib was 100%, odds ratio 18.7 Even more, a study
by Chu et al.8 identiﬁed CAD as the risk factor for CHF in patients
treated with sunitinib with an odds ratio of 17 and for major
adverse cardiac events (cardiovascular death, myocardial infarc-
tion, and CHF) with an odds ratio of 40 (three of the four patients
with a CAD history developed CHD). These are strongly supportive
data for CAD as a paramount risk factor for sunitinib cardiotoxicity
but may apply to VSP inhibitors in general. The latter point may be
supported by the higher relative risk for arterial thromboembolic
events and cardiac ischemia in the aforementioned meta-analysis,
which may translate into CHF, a point to be proven by correlative
studies on patient level.6
The leading concept to explain the association of CAD with VSP
cardiotoxicity relates to the concept of perfusion–contraction
match, i.e., that myocardial contraction is coupled to and a
Table 1. FDA-approved vascular endothelial growth factor signaling pathway inhibitors
Drug (brand name) Molecular targets FDA approved for the treatment of
Aﬂibercept (Zaltrap) Recombinant fusion protein of FLT-1 (VEGF receptor 1) and
KDR (VEGF receptor 2) and immunoglobulin Fc component
that captures (traps) VEGF-A, VEGF-B, and placental growth
factor
Metastatic colorectal cancer
Axitinib (Inlyta) c-KIT, PDGFR-A, PDGFR-B, FLT-1, KDR, FLT-4 (VEGF receptor 3) Advanced renal cell carcinoma
Bevacizumab (Avastin) Anti-VEGF-A antibody Glioblastoma
Persistent/recurrent/metastatic cervical cancer
Metastatic colorectal cancer
Non-small (nonsquamous) cell lung cancer
Ovarian (epithelial), fallopian tube, or primary peritoneal
cancer
Metastatic renal cell cancer
Cabozantinib
(Cabometyx Cometrig)
MET, KDR, FLT3, c-KIT, RET Advanced renal cell carcinoma
Medullary, locally advanced or metastatic thyroid cancer
Lenvatinib (Lenvima) PDGFR-B, FLT-1, KDR, FLT-4, RET, c-KIT Advanced renal cell carcinoma
Advanced thyroid cancer
Pazopanib (Votrient) ABL-1, c-KIT, PDGFR-A, PDGFR-B, FLT-1, KDR, FLT-4, FGFR, c-fms Advanced renal cell cancer
Advanced soft tissue sarcoma
Ramucirumab (Cyramza) Anti-KDR antibody Metastatic non-small cell lung
Metastatic gastric
Metastatic colorectal cancer
Regorafenib (Stivarga) PDGFR-B, FLT-1, KDR, FLT-4, TIE2, RET, c-KIT, RAF Metastatic colorectal cancer, locally-advanced,
unresectable, or metastatic gastrointestinal stromal
tumor, and hepatocellular carcinoma
Sorafenib (Nexavar) B-Raf, FLT-1, FLT-3, FLT-4, KDR, KIT, PDGFR-A, PDGFR-B, FGFR, c-
fms
Hepatocellular carcinoma
Advanced renal cell cancer
Differentiated thyroid cancer
Sunitinib (Sutent) ABL-1, c-KIT, PDGFR-A, PDGFR-B, FLT-1, KDR, FLT-3, FLT-4, FGFR,
SRC, c-smc
Gastrointestinal stromal tumor
Pancreatic neuroendocrine tumors
Renal cell cancer, adjuvant and advance
Vandetanib (Candetanib) EGFR, KDR, FLT-4, RET Medullary, locally advanced or metastatic thyroid cancer
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reﬂection of myocardial blood ﬂow (MBF) perfusion.9,10 This
concept is utilized, for instance, in stress echocardiography
testing.11 The reduction of myocardial perfusion though may
not always be due to a focal coronary stenosis with a related
abrupt drop in perfusion pressure.12 Rather, diffuse luminal
diameter reductions over the epicardial course of the coronary
arteries or several, by themselves not signiﬁcant stenoses can
generate additive effects sufﬁcient enough to decrease perfusion
pressure.12 Furthermore, abnormalities of the coronary micro-
circulation can increase the resistance to such a degree that
impairment of perfusion of the myocardium evolves.12 VSP
inhibitor therapy has the potential to contribute to all of these
mechanisms, and patients with CAD have a conceptually lower
margin of tolerability in this regard.
In a suitable rodent model marked acceleration of athero-
sclerosis was observed with a pan-VEGF receptor TKI.13 Increased
plaque vulnerability, however, was not seen, which has been a
theoretic concern for the use of VSP inhibitors.14 As such, this
observation supports the theory that plaque neovascularization
increases plaque vulnerability and anti-angiogenic therapy favors
plaque stabilization.14 This being said, considering the paramount
signiﬁcance of VSP for vascular hemostasis, it is still not
inconceivable that severe consequences can evolve from VSP
inhibitor therapy, including endothelial cell apoptosis, plaque
erosions, and acute arterial thrombotic events. In fact, very elegant
basic science work conﬁrmed the occurrence of all of these when
autocrine VEGF signaling of endothelial cells was rendered
insufﬁcient.15
Before any of these structural phenomena evolve, VSP signaling
inhibition can have profound functional implications. This relates
to reduced nitric oxide production and the evolving endothelial
dysfunction fosters arterial inﬂammation and atherosclerosis,
platelet reactivity, and vasoconstriction.16 Superimposed on
structural alterations, coronary vasoconstriction can lead to
signiﬁcant reductions in perfusion pressure and myocardial
ischemia. The abnormal vasoreactivity of the coronary micro-
vasculature may be even more profound in its effect.17 A major
advance in this area was the discovery that sunitinib can
signiﬁcantly alter the integrity of the coronary microcirculation
with evident reduction of the coronary ﬂow reserve (CFR) and
impairment of cardiac function.18 Intriguingly, inhibition of the
platelet-derived growth factor (PDGF) signaling pathway seemed
to be responsible for these phenomena, leading to depletion of
the pericyte population, thereby destabilizing endothelial cells,
the coronary microcirculation, and ultimately cardiac function. This
has given recognition to the concept of pericyte–endothelial-
myocardial coupling and the vascular nature of “cardiotoxicity” of
VSP inhibitor therapy.19
At present it is unknown how these discoveries and concepts
are best translated into clinical practice, if and how best to deﬁne
any preexisting or evolving impairment of myocardial perfusion
and the microcirculation that can then manifest in a decrease in
cardiac function. Stress echocardiography could fulﬁll this role and
was mentioned in the ASE consensus document as potentially
being “helpful in the evaluation of patients with intermediate or
high-pretest probability for CAD (echocardiogram uninterpretable
or unable to exercise), who will receive regimens that may cause
ischemia (ﬂuorouracil, bevacizumab, sorafenib, and sunitinib).”20
Echocardiography can be expanded further to include myocardial
perfusion assessment and even CFR.17,21,22 Otherwise, positron
emission tomography (PET) and cardiac magnetic resonance
imaging can be utilized for noninvasive quantiﬁcation of regional
MBF and MBF reserve.17,23,24 Cardiac catheterization would be the
most direct approach, founded on coronary ﬂow velocity (reserve)
measurements, which along with coronary artery diameter
measurements can be used to calculated coronary blood ﬂow.
Alternatively, the index of microvascular resistance can be
calculated.17
Another aspect not clariﬁed at this point is how soon VEGF
inhibitor therapy can be resumed or started after an acute
coronary syndrome/myocardial infarction. As a general timeline
for the healing response, myocytolysis declines after 4 weeks and
the risk of hemorrhage declines sharply after 2 weeks at a point in
time when angiogenesis reaches a plateau.25,26 This corresponds
to changes in the VEGF/VEGF-R expression proﬁle. VEGF-A
expression increases early after myocardial infarction, thereafter
declining. VEGF-B expression, on the other hand, remains
signiﬁcantly suppressed and the expression of VEGF-C and
VEGF-D is signiﬁcantly increased, both early and late after
myocardial infarction. VEGF receptor 3 expression is also
increased, whereas the expression of VEGF receptors 1 and 2 is
decreased. These ﬁndings suggest a functional role for VEGF-C
and VEGF-D via VEGF receptor 3, which has traditionally been
associated with the lymphatic system and may be involved in the
repair process.27 There are no detailed studies looking speciﬁcally
at this aspect of the VSP. One experimental study evaluating the
effect of sorafenib in mice subjected to myocardial infarction did
not ﬁnd evidence of any alteration of post-myocardial infarction
neovascularization or ﬁbrosis.28 However, sorafenib led to
apoptosis of cardiac- and bone-derived c-kit+ stem cells, thereby
decreasing endogenous cardiac repair capacity. Intriguingly, beta-
blocker therapy improved outcomes of sorafenib-treated mice; it
ameliorated myocyte loss, improved cardiac function, and
reduced mortality.28 It will be important to test whether these
observations can be translated into the clinic and to deﬁne the
ﬁeld further. Beta-blocker therapy is standard of care for
myocardial infarction patients already and timelines for starting
or resuming VSP inhibitor after myocardial infarction may match
the perioperative management guidelines, i.e., at least 60 days
should pass from the acute myocardial infarction to subsequent
stressors.29,30
HYPERTENSION AS A RISK FACTOR FOR CARDIOTOXICITY
WITH VSP INHIBITORS
In addition to CAD, clinical studies on cardiotoxicity with sunitinib
therapy outlined hypertension as a risk factor for heart failure.7 In
fact, in the study by Di Lorenzo et al.7 all 12 patients who
developed CHF or grade 3 cardiac dysfunction (left ventricular
ejection fraction (LVEF) 20–39%) had systemic hypertension. In all
but two cases the hypertensive response was of grade 3 degree
(i.e., blood pressure >150mmHg systolic or >100mmHg diastolic
with requirement of more than one antihypertensive or increase
in the dosage of antihypertensive medication).7 Fourteen of the 17
patients developing grade 3 hypertension and nine of the 12
patients developing CHF/grade 3 cardiac dysfunction had
systemic hypertension at baseline (all controlled, no patient had
grade 3 hypertension before sunitinib). The development of grade
3 hypertension had a 70.6% positive predictive value and a 98.7%
negative predictive value for the development of CHF. Of further
interest, all patients had a normal LVEF at baseline, and all of them
had a reduced LVEF at the time of presentation. As outlined in Fig.
1, the presentation of CHF cases evolved over the ﬁrst three cycles,
with one cycle typically being 4 weeks on and 2 weeks off,
whereas the incidence of hypertension continued to rise. Blood
pressure changes were most pronounced over the ﬁrst three
cycles, and the biggest increase in the incidence of grade 3
hypertension and grade 3 cardiac dysfunction was seen from
cycles 2 to 3. This being said, the percentage of patients without
hypertension continued to decline, whereas LVEF dynamics
remained stagnant.7 On the contrary, the ﬁrst comprehensive
study on sunitinib cardiotoxicity in a subset of patients with the
same treatment regimen noted a continuous, gradual decline of
cardiac function despite stabilization of hypertension dynamics
and initiation of beta-blocker and angiotensin converting enzyme
inhibitor therapy in more than half of the cohort.8 Blood pressures
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were controlled to <140/90 mmHg, but compared with baseline
values, they remained signiﬁcantly elevated, raising the question
whether control to baseline levels would be more beneﬁcial.
Taken together, while further studies are needed to deﬁne the
relationship, hypertension may be considered as a signiﬁcant risk
factor for cardiotoxicity with VSP inhibitors and efforts to more
aggressively control blood pressure may be rather beneﬁcial. This
is in keeping with the paradigm forwarded by the SPRINT trial and
the most recent multi-societal guidelines on hypertension.31,32
In a large animal model, resting systemic blood pressure
increases signiﬁcantly within 1 week of starting sunitinib therapy
in conjunction with an increase in systemic (and even coronary)
vascular resistance.33 The potency of this change is underscored
by a decrease in cardiac output occurring already at this stage in
both large and small animal models without any evidence of
abnormal myocardial vascularity and contractility.33,34 With
chronic afterload increase, the heart aims to adapt by hyper-
trophic remodeling (Fig. 2). This hypertrophic response increases
oxygen demand, stimulates the HIF-1a-VEGF axis and eventually
leads to vascular neogenesis in the myocardium, aiming to meet
the heightened metabolic demand.35 Izumiya et al.36 demon-
strated not only cardiac hypertrophy on cardiomyocyte and organ
level, but also an increase in cardiac expression of VEGF-A after
thoracic aortic constriction (TAC) in mice, an established model of
afterload increase. Interestingly, capillary density did not match
the increase in myocardial area, leading to a relative deﬁcit that
was signiﬁcantly increased with the expression of a VEGF receptor
decoy protein. While fractional shortening was lower and left-
ventricular end-diastolic pressure was higher with TAC alone,
these reﬂections of cardiac dysfunction were much more
pronounced in TAC animals expressing the VEGF receptor decoy
protein. The noteworthy association of capillary density (anatomic
microcirculatory reserve) with cardiac function is in keeping with
the principle of perfusion–contraction match, which is not limited
to the epicardial vasculature. Interestingly, these dynamics are
recapitulated in mice treated with the VSP-TKI sunitinib and in
patients treated with VSP inhibitors, who exhibit capillary
rarefaction.18,37 The cardiomyocytes of these mice show mito-
chondrial swelling and degenerative changes, but apoptosis is not
signiﬁcantly increased unless sunitinib treatment is combined
with an increase in blood pressure.8 A reduction in capillary
density, of note, may not become apparent until combined with
an increase in afterload, and afterload increase seems to be the
common denominator for cardiac pathology to evolve.18,38 All in
all these considerations are in support of optimal blood pressure
control in the clinic.
Other prominent clinical examples where hypertension and
cardiomyopathy are at play along with VEGF receptor decoy
dynamics are preeclampsia and peripartum cardiomyopathy.39 In
these women, soluble FLT-1 (sFLT-1), which is the non-membrane
bound VEGF receptor 1 that can function as a decoy for VEGF, is
secreted by the placenta in late gestation and signiﬁcantly
increased circulating levels are noted in women with peripartum
cardiomyopathy, effects that are ampliﬁed when combined with
preeclampsia. In a rodent model, exogenous sFLT-1 causes
diastolic dysfunction and systolic dysfunction under circumstances
of impairment of the metabolic and angiogenic reserve in the
form of PPAR-gamma coactivator (PGC)-1α deﬁciency.39 Of note,
PGC-1α is a transcriptional coactivator that is highly expressed in
Hypertrophic stimuli
Hypoxia/ischemia
Cardiomyocyte
Vasculature
ERK & p38 Akt
GSK3 mTOR
AngiogenesisContractile 
Genes
Hypertrophy VEGF
GATA4 HIF-1α
Fig. 2 Myocardial hypertrophy and angiogenesis. Illustration of the
VEGF-mediated, angiogenesis response to hypertrophic stimuli.
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the heart and has been implicated in anthracycline cardiomyo-
pathy as well.40 PGC-1α is important for antioxidant defense,
mitochondrial homeostasis, and cell metabolism, as well as for the
expression and secretion of pro-angiogenic factors, such as
VEGF.41 PGC-1α deﬁcient mice develop a dilated cardiomyopathy
that is aggravated in the presence of sFLT-1.39 Not surprisingly,
these mice respond poorly to stressful stimuli such as afterload
increase by TAC and their survival is markedly reduced with
increasing numbers of pregnancies, which also progressively
decrease myocardial microvascular density.39 Importantly, provid-
ing VEGF rescues these mice from their detriment and conﬁrms
the vascular pathophysiology of peripartum cardiomyopathy. Very
intriguingly, patients who recover fully from peripartum cardio-
myopathy continue to have signiﬁcantly higher circulating sFlt1
concentrations and signiﬁcantly lower VEGF/sFlt1 ratios along with
abnormal left ventricular (LV) global longitudinal strain values.42
Thus, the angiogenic imbalance persists in these patients along
with subtle evidence of myocardial dysfunction, strengthening the
view of their association.
CONDITIONS OF INCREASED AFTERLOAD OTHER THAN
SYSTEMIC HYPERTENSION AS POTENTIAL MEDIATORS/
MECHANISMS OF VSP-INDUCED CARDIOTOXICITY
The signiﬁcance of the myocardial microvasculature and adaptive
capillary growth for the structure and function of the myocardium
is highlighted to another level in hypertrophic cardiomyopathy.43
Patients affected by this condition have reduced vascular capacity
and CFR.17 This relates to the reduction of capillary density in
correlation with the resting LV outﬂow tract gradient, on average
by one third.44,45 In an experimental hypertrophy model,
administration of recombinant VEGF promoted capillary growth
and reduced cardiomyocyte apoptosis. It furthermore prevented
cardiac dilation and contractility decline, delayed onset of heart
failure, and prolonged survival.46
The outlined dynamics are also applicable to aortic stenosis,
which potently induces cardiac hypertrophy over time, especially
with a progressive increase in the outﬂow tract gradient. These
patients likewise have a reduced CFR related to vascular
rareﬁcation.17 Very evident in adult male mice subjected to aortic
stenosis, the increase in myocardial VEGF expression and capillary
density lags behind the increase in cardiomyocyte area (hyper-
trophy) resulting in perturbed mitochondrial energetics, cardio-
myocyte apoptosis, and a decline in cardiac contractility.47
Overexpression of VEGF in this setting boosts capillary density
and mitochondrial energetics, reduces cardiomyocyte apoptosis,
and preserves cardiac function without a change in cardiac mass
or hypertrophy.47
Another condition associated with increased afterload is OSA.48–
53 The apneic episodes in these patients cause hypoxia and
carbon-dioxide retention sufﬁcient enough to trigger ineffectual
inspiratory efforts and the generation of negative intrathoracic
pressure against the occluded pharynx. By increasing the
difference between intracardiac and extracardiac pressure, LV
transmural pressure increases, i.e., LV afterload.54 The negative
intrathoracic pressure augments venous return and right ven-
tricular (RV) preload, while hypoxia causes pulmonary vasocon-
striction, increasing RV afterload.54 As a consequence, the pressure
and the size of the RV increase with exaggerated interventricular
dependence that reduces LV ﬁlling during diastole and decreases
stroke volume during systole.54 These acute effects were
conﬁrmed in a canine model and animals chronically exposed
developed cardiac hypertrophy and dysfunction.55 The combina-
tion of increasing afterload and hypertrophic stimulus on the one
hand and hypoxemic episodes on the other hand is unique and
may point to greater stimulation of compensatory angiogenesis
via the HIF-1a-VEGF axis.56,57 Of interest, VEGF generation capacity
in response to hypoxia correlates with collateral vessel formation
capacity in CAD patients,58 and an impairment in this response
translates into poorer clinical outcomes.59–61 Endothelial dysfunc-
tion and impaired myocardial perfusion is noted in otherwise
normal subjects with moderate-to-severe OSA.62 Increases in
sympathetic tone can further peripheral vasoconstriction and
increase afterload. These dynamic effects of OSA may persist way
into the awake period and can lead to sustained blood pressure
elevations over time.54 As such OSA is not only strongly and
independently associated with blood pressure elevation, but even
resistant systemic hypertension and reinforces all of its con-
sequences.54,63 Accordingly, when seeing patients for VSP
inhibitor therapy it may be important to review not only whether
systemic hypertension is present, but also which conditions could
play a contributing role to and/or increase afterload beyond overt
systemic hypertension.
HYPOTHYROIDISM AS A POTENTIAL MEDIATORS/
MECHANISMS OF VSP-INDUCED CARDIOTOXICITY
In a review on “understanding and managing toxicities of VEGF
inhibitors” Schmidinger forwarded the view that hypothyroidism
induced by VSP-TKIs can contribute to their cardiotoxicity
potential.64 Up to 85 and 21% of patients on sunitinib and
sorafenib, respectively, develop subclinical or clinically overt
hypothyroidism.65 Of note, both of these drugs have been used
in the treatment of thyroid carcinoma owing to their potency to
inhibit kinases involved in the growth and function of thyroid
cells. VSP inhibitor-induced hypothyroidism is seen as a con-
sequence of inhibition of the ret proto-oncogene product,
suppression of iodine uptake and peroxidase activity, and
induction of capillary regression.64 Regression of capillaries has
been observed in a number of organs (especially endocrine
organs) in adult rodents treated with VSP inhibitors.66 In the study
by Chu et al.,8 ﬁve out of 36 patients (14%) on sunitinib developed
hypothyroidism at a mean time of 54 weeks. While the incidence
of heart failure in these patients was not reported, it was stated
that the mean time to onset of heart failure was only half of this
time interval and that CHF preceded hypothyroidism in all
patients.8 On the other hand, one of the highest incidences of
cardiotoxicity with VSP inhibitor is observed among patients with
thyroid cancer.67 These patients are confronted with hypothyroid-
ism as consequence of their therapy. Importantly, even subclinical
hypothyroidism, low T3 levels, and borderline normal thyroid
function can translate into impaired endothelial function (vasor-
elaxation), increased SVR, reduced cardiac output, and worse
cardiovascular outcomes.68–70 A reduction in cardiac output is felt
to be the consequence of a decrease in heart rate, cardiac ﬁlling
(i.e., preload in addition to increased afterload), and cardiac
contractility.71,72 Thus, while there is no sequential or otherwise
direct evidence that hypothyroidism induced by VSP-TKIs is causal
to the cardiotoxicity risk of these drugs, it remains important to
diagnose and treat hypothyroidism in any cancer patient
throughout the continuum of their care. The vascular and
hemodynamic changes induced by clinical and even subclinical
hypothyroidism are similar and presumably additive to those
induced by VSP inhibitor therapy.8,67,73–79
DIABETES MELLITUS AS A POTENTIAL MEDIATOR/MECHANISM
OF VSP-INDUCED CARDIOTOXICITY
Another condition associated with dysfunction of the coronary
microvasculature and the development of cardiomyopathy is
diabetes. A decline in cardiac function and progressive myocardial
ﬁbrosis over time has been demonstrated in experimental models
of diabetes. This is associated with a concomitant decrease in
myocardial capillary density and MBF.80 VEGF165 gene therapy by
plasmid vector delivery counteracts these developments and
provides a “cure.” As important as these observations are for the
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speciﬁc disease process, they also raise awareness that any
additional interference with angiogenesis could be potentially
more harmful for patients with diabetes. A progressive decline in
CFR has, indeed, been observed in patients across the spectrum of
diabetic disease severity that makes these patients more
vulnerable.
In metastatic renal cell cancer patients VSP-TKIs were found to
decrease blood glucose levels in both nondiabetics and dia-
betics.81 The effects can be profound, and diabetics may stop their
medications. Inhibition of insulin clearance was found to be one
mechanism, and hypoglycemic episodes can develop in patients
using insulin or insulin-secretion stimulating agents. Other
mechanisms discussed include capillary regression of pancreatic
islets. Indeed, this has been observed in a mice, and sunitinib
increased insulin sensitivity and peripheral glucose uptake.82
Sunitinib also increased glucose uptake in the heart 5-fold in
conjunction with increased glucose metabolism and caused
upregulation of enzymes of the glycolytic pathway, particularly
the M2 isoform of pyruvate kinase, reﬂecting activation of the fetal
gene program.82 These dynamics are enhanced by HIF-1 alpha
activation, and thus aggravated by ischemia/hypoxia, either due
to reduced blood supply or increased demand in the setting of
hypertrophic disease processes. Of note, diabetic hearts are
characterized by reduced glucose and glycolysis and enhanced
fatty acid metabolism and it has been discussed that altered
myocardial substrate and energy metabolism may contribute to
the development of diabetic cardiomyopathy.83–89 One may thus
argue that the pro-glycolytic action of sunitinib may be beneﬁcial.
However, two recent reports conﬁrm that sunitinib increases
cardiac glucose uptake and reliance on glycolysis, but there is
failure to use glucose as an energy substrate (similar to insulin
resistance and diabetic states). Even more, there is evidence of
reduced oxidative phosphorylation, increased myocardial lipid
deposition, and perturbed mitochondrial function, in keeping with
the view of that sunitinib induces a fundamental energy crisis that
results in compromised myocardial energy metabolism and
function.90,91
In this context, the inhibitory effects of sunitinib on AMP kinase
described previously gain further signiﬁcance.92–94 This enzyme
senses the energy state of cells and responds to increases in AMP:
ATP and ADP:ATP ratios, reﬂecting energy rundown or energy
stress, with activation of catabolic pathways that generate ATP.95
This includes the stimulation of glucose uptake and glycolysis, as
well as oxidative phosphorylation and PGC-1 alpha, the signiﬁ-
cance of which was mentioned in the context of peripartum
cardiomyopathy before. AMP kinase also has an important role for
the stimulation of autophagy as an important process for organ
viability. Under normal conditions, the signiﬁcance of AMP kinase
in controlling these processes is not as evident, but under
ischemic stress conditions, deﬁciencies in these domains translate
into a larger extent of myocardial injury/infarction and poorer
recovery of cardiac function.96 These observations also provide an
illustration of the potential impact of impairment of AMP kinase
activity by sunitinib.92–94 Interestingly, metformin has been shown
to enhance AMP kinase activity with cardioprotective effects in
experimental models of ischemia/reperfusion injury, myocardial
infarction, and anthracycline cardiotoxicity.97–103 Metformin has
also been noted to be of beneﬁt in dilated cardiomyopathy and
prevents hypertrophy, which is of particular interest in the context
of VSP inhibitors.104–112 If and how metformin could be utilized to
counteract sunitinib cardiotoxicity or cardiomyopathy related to
VSP inhibitor use in general and in patients with diabetes in
particular is unknown but the hypothesis-generating data
presented here would support such studies.8,64,65,67,73–79 Addi-
tional studies are also needed to deﬁne the risk equation for
diabetic patients undergoing VSP inhibitor more accurately. Yet
for now, conceptually it does seem prudent to error on the side of
caution and to be considerate of their cardiovascular adverse
event potential.
CHEMOTHERAPY AS A POTENTIAL MEDIATOR/MECHANISM OF
VSP-INDUCED CARDIOTOXICITY
Another aspect to be considered is preceding or concomitant
cancer therapy, potent enough to exert injury to the heart and/or
its vasculature. Indeed, this occurs with various chemotherapeu-
tics and radiation therapy to the chest. Again, inhibition of the VSP
at a time when its activation is needed for recovery from injury
can be detrimental. An example is provided in the MAIN trial,
which randomized patients with diffuse large B-cell lymphoma to
R-CHOP therapy with placebo or bevacizumab (10mg/kg q
2 weeks or 15mg/kg q 3 weeks). The trial was stopped after
enrollment of 787 patients by the Data and Safety Monitoring
Board because of a nearly 3-fold higher risk of drop in LVEF and
heart failure in the absence of any therapeutic beneﬁt.113 Given
the multidrug nature of the R-CHOP regimen (Rituximab,
Cyclophosphamide, doxorubicin hydrochloride (Hydroxydaunor-
ubicin), vincristine sulfate (Oncovin), and Prednisone), the nature
of the most signiﬁcant interaction remains elusive.
Cyclophosphamide, for instance, can induce endothelial injury
and apoptosis and thus has clear interaction potential with VSP
inhibitors as does vincristine. Doxorubicin alters paracrine VEGF
signaling in the myocardium, upregulating VEGF-A release from
cardiac microvascular endothelial cells (CMECs) but decreasing
VEGF receptor 2 expression in both CMECs and adult ventricular
myocytes.114 In a cell culture model, (over-) expression of VEGF-
A165 was found to protect cardiomyocytes from doxorubicin-
induced apoptosis, related to upregulation of the Akt pro-survival
signaling pathway.115
Another in vivo study showed that VEGF-B186 also exerts
cardioprotective effects in mice subjected to doxorubicin.116
VEGF-B186 protected not only cardiomyocytes from injury, but
also endothelial cells and the myocardial microvascular network.
The potency of the VEGF-B186 effect on endothelial cells is
underscored by its capacity to preserve endothelial function, a
very sensitive marker of endothelial health. This beneﬁcial effect
was related to the robust expression of VEGF receptor 1 on
endothelial cells in the myocardium.117 Of note, following
myocardial infarction, prolonged intramyocardial expression of
VEGF-A165 and VEGF-B167 preserves viable cardiac tissue, prevents
ventricular remodeling, and results in improved cardiac function
over time. The increase in contractile myocardium was more
pronounced after expression of VEGF-B, even in the absence of
signiﬁcant induction of angiogenesis. VEGF-B signals through the
VEGF-R1 receptor, which was upregulated under conditions of
hypoxia and oxidative stress and elicited a particular gene
expression proﬁle of the compensatory, hypertrophic response,
both in cultured cardiomyocytes and in infarcted hearts. This
translated into powerful anti-apoptotic effect of VEGF-B in
cardiomyocytes and mouse hearts in vivo.118 Cardioprotective
effects of VEGF-B167 unrelated to angiogenesis were also
conﬁrmed in an experimental (pacing-induced) non-ischemic
dilated cardiomyopathy model.119 VEGF-B did not change
microvascular density but reduced the number of apoptotic
cardiomyocytes in the heart, preserved systolic and diastolic
cardiac function, and prevented LV wall thinning.
In cultured rat neonatal cardiomyocytes exposed to angiotensin
II, VEGF-B167 prevented oxidative stress, loss of mitochondrial
membrane potential, and, consequently, apoptosis.119 Thus, in
addition to VEGF-A and the VEGF recptor-2, which has been the
focus of the beneﬁcial effects and side effects of VSP inhibitors,
the above ﬁndings provide a different perspective. VSP inhibitors
with an additional inhibitory effect on the activity of VEGF
receptor 1 may therefore bear a higher risk of cardiotoxicity. While
this may hold true for sunitinib in some studies, this has not been
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conﬁrmed on a broader scale. Neither has pazopanib, which has
additional anti-VEGF receptor 1 inhibitory properties, nor the pan-
VEGF receptor TKI axitinib, been associated with a higher
incidence of cardiotoxicity. Moreover, in preclinical screening
studies, the therapeutic window of VSP antagonists was fairly
comparable and not inﬂuenced by VEGF receptor 1 inhibiting
properties.120 One may therefore conclude that the VEGF-B-VEGF
receptor 1 axis is of beneﬁt if stimulated, but its inhibition may not
be detrimental per se. For the interaction with other chemother-
apeutics, the most important consideration is the very likely
additive adverse action on endothelial cells. While VEGF is
expressed even in the normal myocardium, the consequences
are most likely revealed when its expression is upregulated as part
of a healing or compensation response, and it is under such
circumstances that most cases of cardiotoxicity occur. The optimal
time interval (if any) between the administration of VSP inhibitors
and other vaso- and/or cardiotoxic agents remains to be deﬁned.
Overall, it is advisable to consider all possible multiple hits in any
given cancer patients, which collectively may reduce the
cardiovascular reserve (over time).121
UNIQUE ASPECTS OF VSP INHIBITOR CARDIOTOXICITY
The healthy myocardium expresses all isoforms of VEGF and all
three VEGF receptor subtypes. While VEGF-B, -C, and –D have
generated some interest, the focus of VSP inhibitor therapy is still
on VEGF-A and its main angiogenic receptor VEGF receptor 2. As
outlined, this axis is stimulated by hypoxia and ischemia, as well as
stretch in the heart, i.e., afterload increases, such as hypertension,
both of which are risk factors for cardiotoxicity with VSP inhibitor
therapy.122 The signiﬁcance of this pathway has been delineated
in conditional knockout mice in which VEGF expression is reduced
in a cardiac-speciﬁc manner. Such intervention translated into a
deceased microvascular density, as well as a suppressed cardiac
function and reserve in keeping with the perfusion–contraction
paradigm.123 Cardiomyocytes release VEGF upon exposure to
various stressors, which then acts on microvascular endothelial
cells in a paracrine fashion.15
Importantly, however, there is also auto-/intracrine signaling,
i.e., the microvascular endothelial cells themselves express VEGF,
which is of utmost signiﬁcance for their survival. In fact, in the
absence of auto-/intracrine VEGF, paracrine sources are not
sufﬁcient to sustain endothelial cell survival.15 Of further
signiﬁcance then, the action of VSP inhibitors acting on the
extracellular domain of the VEGF receptor, i.e., the monoclonal
antibodies can be overcome, whereas this is not the case for those
acting at the intracellular sites of the receptor, such as VSP-TKIs.
The actions of the latter drugs can thus be more profound. The
potential for harm may be even greater the lower their target
speciﬁcity. This has been suggested by the results of myocyte cell
culture studies.124 Such promiscuity may extend to other receptor
tyrosine kinases.
For instance, as mentioned above, sunitinib inhibits PDGFR
receptor-ß tyrosine kinase as well. This translates into reduced
myocardial pericytes, decreased myocardial microvascular density,
and a further reduction in cardiac function when mice were
subjected to sunitinib in addition to TAC.18 These ﬁndings
highlight the importance of pericyte-endothelial-myocardial
coupling (Fig. 3) and the signiﬁcance of the integrity of the
vasculature for cardiac function and reserve and help explain
some reports on the association of cardiac troponin (cTn)
elevation with the use of VSP-TKIs but not bevacizumab or mTOR
inhibitors, even though all induce a comparable degree of
hypertension and cardiac dysfunction.125 However, even though
incidences may vary between the different agents and across
different populations, comprehensive studies on this subject were
unable to conclude that the (relative) risk of cardiotoxicity is
higher with one type of VSP inhibitor than another and neither do
meta-analyses describe notable differences in cardiovascular risk
between direct VEGF inhibitors and small molecule agents.6,126–130
Thus, regardless of the extracellular mode of action on VEGF-A
(bevacizumab) or intracellular mode of action on various VEGF
subtypes, either selective to all VEGF receptor TKIs (axitinib) or
non-selective to VEGF receptor TKIs and other TKI targets (e.g.,
sorafenib, sunitinib, and pazopanib), there are speciﬁc character-
istics inherent/generic to VSP inhibition.
In a mouse model, treatment with bevacizumab led to a similar
increase in blood pressure, drop in LVEF, extent of LV dilation,
circulating cTn levels, and ultrastructural changes of the myocar-
dium than treatment with sunitnib.131 Of note, the increase in
blood pressure preceded the development of cardiotoxicity by
1 week. No interventions were performed to evaluate if any
antihypertensive action would have changed the cardiac out-
comes. The study, however, did make the point that any type of
VSP inhibition, including VEGF-A directed therapy, has cardiotoxic
potential.
Endothelial cell
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PDGFRβ
PDGFβTie2
Ang-1VEGF
VEGFR
NRG-1
ErbB4 ErbB2 M2
NO
VEGFR Tie2
Ang-1
VEGF
SurvivalStructure Function
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Fig. 3 Pericyte–endothelial–myocardial coupling. Illustration of pericyte–endothelial–myocardial coupling. None of these cells exists in
isolation in the myocardium, but there is interaction on multiple levels. Accordingly, cardiomyocytes can be affected by an initial action on
endothelial/pericyte level. This has been shown for sunitnib, although it has been reported to affect all three outlined cell types
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MONITORING AND TREATMENT OF CARDIOTOXICITY WITH
VSP INHIBITORS
An important feature of VSP inhibitor-induced cardiotoxicity is its
reversibility in most but not all (60–80%) of patients upon
withdrawal.7,132,133 Indeed, prompt recognition and cessation of
VSP inhibitor therapy is the single most important step to
recovery, and the institution of classic heart failure therapy has
been viewed to be more of an ancillary than crucial element.7,133
Cessation of VSP inhibitor treatment, however, is suboptimal from
a cancer therapy perspective, and balancing the beneﬁts and risks
of VSP inhibitor cancer therapy is important yet challenging.
VSP inhibitor-induced cardiotoxicity is considered to be remi-
niscent of that observed with the HER-2 inhibitor trastuzumab. It
differs from classical anthracycline cardiotoxicity not only by its
reversible nature, but also by its lack of dose response and lack of
inﬂuence of subsequent stressors and tolerance of reexposure. As
outlined in the 2014 consensus documents of the American
Society of Echocardiography and the European Association of
Cardiovascular Imaging on multimodality imaging of adult patients
during and after cancer therapy,20 patients undergoing VEGF
inhibitor therapy are to be monitored every 3 months for the time
of treatment with 2D (with contrast) or 3D echocardiograms. In
distinction from other cancer therapeutics for which a similar type
of cardiotoxicity has been described, the ﬁrst follow-up evaluation
of cardiac function should be one month after therapy with VSP
inhibitors as cardiotoxicity can emerge sooner and sometimes very
early on. Such dynamics are likely the reﬂection of the state of
“angiogenic dependence” of the myocardium.
The 2014 ASE/EACI consensus document recommendations
include strain imaging and cTn assessment in the algorithm of
assessment 1 month and then every 3 months after start of
therapy. One of the most comprehensive initial evaluations of
sunitinib cardiotoxicity found that while 8% of the 75 patients
enrolled developed heart failure, 80% of patients experienced
some degree of LVEF decline (≥10 and ≥15% in nearly 30 and 20%
of patients, respectively).8 The LVEF dynamics, however, were
assessed only for 36 of these patients who had been on 50mg of
sunitinib per day, 4 weeks on and 2 weeks off. Based on repeated-
measures, mixed-model regression analysis, it was predicted that
LVEF would drop by 2% with the ﬁrst and 1.5% with subsequent
cycles. However, marked interindividual differences exist support-
ing close follow-up recommendations, and as the median time for
heart failure was 31 weeks (range 11–85 weeks), over a prolonged
period of time. Only one study has been published so far reporting
on strain imaging in these patients. Global longitudinal strain
decreased within 2 weeks of initiation of treatment and continued
to decline further in those maintained on therapy.134 This was in
the absence of any early change in LVEF, but how predictive it is
for future LVEF drops is not known.
With regards to cTn, a similar-sized study of 74 consecutive
patients treated with sunitinib or sorafenib for mRCC noted cTnT
elevation in nine patients.135 In all but two of these patients the
cTnT values were <0.1 ng/mL. Two thirds of the elevations were
associated with ECG changes, slightly less than half had a reduced
LVEF. Vice versa, four of the seven patients with a reduce LVEF and
six of the 12 patients with ECG changes had cTnT elevation. Data
on reversibility of cardiac dysfunction were not provided, but in all
but one case VSP inhibitor therapy could be resumed, suggesting
that cTnT elevation may not be a marker of irreversible
cardiotoxicity in these patients. In agreement, another prospective
study on 90 patients undergoing therapy predominantly with a
VSP inhibitor found that ten patients developed chest pain, two of
which had cTnI elevation, and eight had asymptomatic cTnI
elevation. An abnormal LVEF and T-wave inversion were seen only
in one patient each. No patient showed late gadolinium
myocardial enhancement on cardiac magnetic resonance or had
stenoses >50% on coronary angiography. All patients with either
chest pain or cTnI elevation received beta-blocker and aspirin and
were then re-challenged with the study drug without recurrent
cardiovascular events.135 Thus, in patients on VSP inhibitor therapy
cTn is not a sensitive marker for either the development or the
irreversibility of cardiac dysfunction (“cardiotoxicity”).
One aspect not taken into consideration in any recommenda-
tion on monitoring and managing of cardiovascular toxicities with
VSP inhibitor therapies is the evaluation and treatment of any
potentially underlying and contributing comorbidity (Figs. 4 and
5). It is important that VSP inhibitor is not considered the culprit by
default, even though it likely has a contributing role in the
majority of cases. The real question in clinical practice often is
whether it is the only factor or whether it unmasks an underlying
disease state and the “angiogenic demand” of the patient. In the
latter scenario, rechallenge may not be well tolerated until the
underlying disease process is treated. Another important aspect is
the quality of blood pressure management. Tighter blood pressure
control, possibly with ambulatory and home blood pressure
monitoring, may be helpful in this regard. Moreover, in patients
with OSA, proper CPAP treatment may reduce the risk of VSP
inhibitor-induced cardiac disease.
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Fig. 4 Conceptual outline of the vascular nature of VSP inhibitor
cardiotoxicity. Outline of the concept of absolute or relative and
structural or functional coronary microvascular deﬁcit and cardio-
myopathy with VSP inhibitor therapy
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CONCLUSIONS
A decline of cardiac function can occur in a subset of patients on
VSP inhibitor therapy. To date, clear guidelines are lacking on how
to risk-stratify and manage these patients. With increased
evidence-based studies, however, comprehensive guidelines
should become available to help diagnose and better manage
VSP inhibitor-induced cardiovascular disease. In this review, we
aimed to provide a conceptual framework that will help to
understand and stimulate more studies on the pathophysiology of
VSP inhibitor cardiotoxicity. Knowing the pathomechanisms and
conditions will allow treating patients with VSP inhibitor therapy
with a more precise understanding of the risk and mitigation
strategies for cardiotoxicity. While acute fatal outcomes are rare,
cardiotoxicity can carry a high burden of morbidity and can impair
long-term outcome. Pro-actively recognizing and managing
vascular and overall health issues of patients undergoing cancer
therapy with VSP inhibitors is precisely for this: to enable patients
to undergo such prognostically extremely important therapy
uncoupled from the risk of cardiovascular diseases.
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